The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10481 malaria professionals are enjoying the free benefits of MalariaWorld today


Efficacy and safety of artesunate–amodiaquine and artemether–lumefantrine and prevalence of molecular markers associated with resistance, Guinea: an open-label two-arm randomised controlled trial

June 26, 2020 - 11:07 -- Open Access
Abdoul Habib Beavogui, Alioune Camara, Mateusz M. Plucinski, et al.
Malaria Journal 2020 19:223, 24 June 2020

Anti-malarial resistance is a threat to recent gains in malaria control. This study aimed to assess the efficacy and safety of artesunate–amodiaquine (ASAQ) and artemether–lumefantrine (AL) in the management of uncomplicated malaria and to measure the prevalence of molecular markers of resistance of Plasmodium falciparum in sentinel sites in Maferinyah and Labé Health Districts in Guinea in 2016.

NOT Open Access | Evolution of antimalarial drug resistance markers in the reservoir of Plasmodium falciparum infections in the Upper East Region of Ghana

May 29, 2020 - 14:38 -- NOT Open Access
Narh CA, Ghansah A, Duffy MF, Ruybal-Pesántez S, Onwona CO, Oduro AR, Koram KA, Day KP, Tiedje KE
J Infect Dis. 2020 May 27:jiaa286

The majority of Plasmodium falciparum infections, constituting the reservoir in all ages, are asymptomatic in high transmission settings in Africa. The role of this reservoir in the evolution and spread of drug resistance was explored.

Genotypes and phenotypes of resistance in Ecuadorian Plasmodium falciparum

December 17, 2019 - 15:56 -- Open Access
Gabriela Valenzuela, L. Enrique Castro, Julio Valencia-Zamora, Claudia A. Vera-Arias, Petra Rohrbach and Fabián E. Sáenz
Malaria Journal 2019 18:415, 10 December 2019

Malaria continues to be endemic in the coast and Amazon regions of Ecuador. Clarifying current Plasmodium falciparum resistance in the country will support malaria elimination efforts. In this study, Ecuadorian P. falciparum parasites were analysed to determine their drug resistance genotypes and phenotypes.

Not Open Access | Evolution of resistance in vitro reveals mechanisms of artemisinin activity in Toxoplasma gondii

December 10, 2019 - 08:43 -- NOT Open Access
Rosenberg A, Luth MR, Winzeler EA, Behnke M, Sibley LD
Proc Natl Acad Sci U S A. 2019 Dec 5. pii: 201914732

Artemisinins are effective against a variety of parasites and provide the first line of treatment for malaria. Laboratory studies have identified several mechanisms for artemisinin resistance in Plasmodium falciparum, including mutations in Kelch13 that are associated with delayed clearance in some clinical isolates, although other mechanisms are likely involved.

NOT Open Access | Prevalence of mutations in Plasmodium falciparum genes associated with resistance to different antimalarial drugs in Nyando, Kisumu County in Kenya

November 26, 2019 - 13:55 -- NOT Open Access
Musyoka KB, Kiiru JN, Aluvaala E, Omondi P, Chege WK, Judah T, Kiboi D, Nganga JK, Kimani FT.
Infection, Genetics and Evolution, 19 November 2019, 104121

Resistance to the mainstay antimalarial drugs is a major concern in the control of malaria. Delayed Plasmodium falciparum parasite clearance has been associated with Single Nucleotide Polymorphisms (SNPs) in the kelch propeller region (K13). However, SNPs in the Pf-adaptor protein complex 2 mu subunit (Pfap2-mu), Pfcrt and Pfmdr1 are possible markers associated with multi-drug resistance. Here, we explored the prevalence of SNPs in the K13, Pfap2-mu, Pfcrt, and Pfmdr1 in 94 dried blood spot field isolates collected from children aged below 12 years infected with P. falciparum during a cross-sectional study.


Research: Persistence of markers of chloroquine resistance among P. falciparum isolates recovered from two Nigerian communities

February 27, 2014 - 22:36 -- Ingeborg van Schayk
Yetunde A. Olukosi, Muyiwa K. Oyebola, Olusola Ajibaye, Bassey A. Orok, Olugbenga O. Aina, Chimere O. Agomo, Bamidele A. Iwalokun, Samuel K. Akindele, Veronica N.V. Enya, Hilary I. Okoh
MWJ 2014, 5, 3

We investigated the prevalence of the major markers of chloroquine resistance years after the withdrawal of the drug in Nigeria.
 Finger prick blood samples were collected from participants presenting with symptoms of malaria in Lagos, Nigeria.

Can we maintain effectiveness of the tools?

May 17, 2012 - 12:30 -- Bart G.J. Knols

This week WHO reiterated the fragility of the gains the world has made over the last decade through intense deployment of vector control in the fight against malaria. Reuters published an online article on the matter titled 'Insecticide resistance threatens malaria fight'. In it, WHO Director General, Margaret Chan, warns of the seriousness of the situation in Africa and India. Apparently, in ever more places the toolbox, filled with four classes of chemicals, is gradually emptying.

Waking up in the face of resistance?

July 7, 2011 - 15:54 -- Bart G.J. Knols

Sometimes you come across articles that blow your mind. You read them and feel your heartbeat increasing. Each sentence you finish makes you wonder more what is going on here. What the politics are, who's really behind it, and what the goal of it is....

ACTs: What will happen when the cat gets out of the bag?

April 11, 2011 - 20:47 -- Bart G.J. Knols

Most of us that have worked in the field of malaria for a few decades have gone through periods where we suddenly noticed changes in drug policy. When chloroquine was replaced by sulfadoxine-pyremethamine as a first-line drug, later to be replaced by artemisinin combination therapies (ACTs).

But the world is now faced with a new challenge. That of preventing artemisinin resistance from escaping south-east Asia. Without anything to replace it (yet), this is a looming catastrophe, according to Joel Breman in an interview with It may still be confined to the Thai-Cambodia border, although nobody really nows have far it has spread.

Subscribe to RSS - resistance